Featured Research

from universities, journals, and other organizations

New Kidney Disease Drug Saves Lives At Low Cost

Date:
December 3, 2005
Source:
Blackwell Publishing Ltd.
Summary:
A recent study has found that sevelamer (Renagel) is having a positive long term clinical and economic effect when used on hemodialysis patients. This study, undertaken by the Caro Research Institute in Concord, MA and published in Value in Health, examined the long-term consequences associated with one year of sevelamer use.

A recent study has found that sevelamer (Renagelฎ) is having a positive long term clinical and economic effect when used on hemodialysis patients. This study, undertaken by the Caro Research Institute in Concord, MA and published in Value in Health, examined the long-term consequences associated with one year of sevelamer use.

"The safety and efficacy of sevelamer and its ability to attenuate the progression of calcification have been well documented in a seminal clinical study, but the study was not designed to assess the longer-term implications," says Krista Huybrechts who led the study.

Huybrechts' team developed a simulation model based on the best available evidence to date, and estimated that in the long-term, patients on sevelamer have a 12% lower cardiovascular risk than those on calcium binders. The cost savings accrued due to avoiding cardiovascular events largely offset the higher drug cost, leading to a very favorable cost-effectiveness ratio of about $2,200 of increased cost per life year gained.

The results of this study now allow health policy makers and payers to understand the value of sevelamer in the long-term where it could not have been done from the clinical study alone.

Close to 500,000 Americans suffer from Stage V chronic kidney disease (CKD) and have a 10-20 times higher risk of cardiovascular mortality than the general population.

###

This study is published in Value in Health.

Krista Huybrechts, MS, is a Senior Researcher at the Caro Research Institute in Concord, MA, USA, which specializes in epidemiology and health economics. Prior to joining Caro Research in 1997, Krista held several positions in health economics/outcomes research at the worldwide headquarters of Janssen Pharmaceutica (J&J) in Belgium. Much of her work in recent years has focused on quantifying the clinical and economic implications of vascular calcifications in patients with ESRD.

About Value in Health
As the official publication of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Value in Health provides a scientific forum for communicating health economics and outcomes research methods and findings, furthering ISPOR's vision that "society allocate scarce health care resources wisely, fairly, and efficiently." It is a multidisciplinary peer-reviewed journal reporting on evaluations of medical technologies including pharmaceuticals, biologics, devices, procedures, and other health care interventions.

About Blackwell Publishing
Blackwell Publishing is the world's leading society publisher, partnering with more than 600 academic and professional societies. Blackwell publishes over 750 journals annually and, to date has published close to 6,000 text and reference books, across a wide range of academic, medical, and professional subjects.


Story Source:

The above story is based on materials provided by Blackwell Publishing Ltd.. Note: Materials may be edited for content and length.


Cite This Page:

Blackwell Publishing Ltd.. "New Kidney Disease Drug Saves Lives At Low Cost." ScienceDaily. ScienceDaily, 3 December 2005. <www.sciencedaily.com/releases/2005/12/051202133842.htm>.
Blackwell Publishing Ltd.. (2005, December 3). New Kidney Disease Drug Saves Lives At Low Cost. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/12/051202133842.htm
Blackwell Publishing Ltd.. "New Kidney Disease Drug Saves Lives At Low Cost." ScienceDaily. www.sciencedaily.com/releases/2005/12/051202133842.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins